Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective

被引:84
作者
Abassi, Zaid
Nakhoul, Farid
Khankin, Eliyahu
Reisner, Shimon A.
Yigla, Mordechai
机构
[1] Rambam Hlth Care Campus, Dept Nephrol, IL-35254 Haifa, Israel
[2] Rambam Hlth Care Campus, Dept Cardiol, IL-35254 Haifa, Israel
[3] Rambam Hlth Care Campus, Div Pulm Med, IL-35254 Haifa, Israel
[4] Technion Israel Inst Technol, Rappaport Fac Med, Rappaport Family Inst Res Med Sci, Dept Physiol & Biophys, Haifa, Israel
关键词
arteriovenous access; calcification; cardiac output; end-stage renal disease; pulmonary hypertension;
D O I
10.1097/01.mnh.0000232874.27846.37
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Purpose of review End-stage renal disease patients receiving chronic haemodialysis via arteriovenous access often develop various cardiovascular complications, including vascular calcification, cardiac-vascular calcification and atherosclerotic coronary disease. This review describes recently published studies that demonstrate a high incidence of pulmonary hypertension among patients with end-stage renal disease receiving long-term haemodialysis via a surgical arteriovenous fistula. Both end-stage renal disease and long-term haemodialysis via arteriovenous fistula may be involved in the pathogenesis of pulmonary hypertension by affecting pulmonary vascular resistance and cardiac output. Recent findings Morbidity and mortality from cardiovascular disease are greatly increased in patients on maintenance haemodialysis therapy. Using Doppler echocardiography, we found a significant increase in cardiac output in 40% of chronic haemodialysis patients, probably related to the large arteriovenous access or altered vascular resistance as a result of the local vascular tone and function expressed by the imbalance between vasodilators such as nitric oxide, and vasoconstrictors such as endothelin-1. Summary We propose different potential mechanisms as explanations for the development of pulmonary hypertension. Hormonal and metabolic derangement associated with end-stage renal disease might lead to pulmonary arterial vasoconstriction and an increase in pulmonary vascular resistance. Pulmonary arterial pressure may be further increased by high cardiac output resulting from the arteriole-venous access itself, worsened by commonly occurring anaemia and fluid overload.
引用
收藏
页码:353 / 360
页数:8
相关论文
共 41 条
[1]
Pulmonary hypertension in patients with chronic renal failure - Role of parathyroid hormone and pulmonary artery calcifications [J].
Amin, M ;
Fawzy, A ;
Hamid, MA ;
Elhendy, A .
CHEST, 2003, 124 (06) :2093-2097
[2]
Primary pulmonary hypertension - A vascular biology and translational research "work in progress" [J].
Archer, S ;
Rich, S .
CIRCULATION, 2000, 102 (22) :2781-2791
[3]
Pulmonary arterial hypertension - The key role of echocardiography [J].
Bossone, E ;
Bodini, BD ;
Mazza, A ;
Allegra, L .
CHEST, 2005, 127 (05) :1836-1843
[5]
Endothelial dysfunction in the pulmonary vascular bed [J].
Chen, YF ;
Oparil, S .
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2000, 320 (04) :223-232
[6]
Reversal of pulmonary hypertension after ligation of a brachiocephalic arteriovenous fistula [J].
Clarkson, MR ;
Giblin, L ;
Brown, A ;
Little, D ;
Donohoe, J .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 40 (03)
[7]
PULMONARY CALCIFICATION IN CHRONIC DIALYSIS PATIENTS - CLINICAL AND PATHOLOGIC-STUDIES [J].
CONGER, JD ;
HAMMOND, WS ;
ALFREY, AC ;
CONTIGUGLIA, SR ;
STANFORD, RE ;
HUFFER, WE .
ANNALS OF INTERNAL MEDICINE, 1975, 83 (03) :330-336
[8]
SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[9]
Pathophysiological mechanisms of vascular calcification in end-stage renal disease [J].
Davies, MR ;
Hruska, KA .
KIDNEY INTERNATIONAL, 2001, 60 (02) :472-479
[10]
Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157